Date: 2014-10-16
Type of information: Presentation of results at a congress
phase:
Announcement:
Company: Osiris Therapeutics (USA - MD)
Product: wound care related studies
Action mechanism:
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: * On October 16 2014, Osiris Therapeutics, a cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced that the company will present findings of three wound care related studies this Friday, October 17 , at the Symposium on Advanced Wound Care in Las Vegas, Nevada . The three presentations include: • A Comparison Study Between Cryopreserved and Non-cryopreserved Human Amniotic Membrane. This study demonstrates that preserving all tissue components, including the three-dimensional tissue matrix architecture, growth factors, tissue resident epithelial cells, fibroblasts and mesenchymal stem cells, is critical for tissue functionality.
• Positive Effects of Cryopreserved Amniotic Membrane on Diabetic Wound Environment. The data indicates that using a proprietary system for tissue processing and cryopreservation is essential to ensure the highest levels of wound healing activities of placental membranes and that a combination of dehydrated amnion and chorion does not compensate for tissue cell destruction, extracellular matrix alterations, and growth factor degradation due to dehydration.
• Use of a Cryopreserved Placental Membrane for Chronic Wounds in Patients with Autoimmune Disorders. Treating chronic wounds in patients with autoimmune diseases poses challenges to healthcare providers because of the chronic inflammatory nature of the wounds and the patients\' exposure to immunosuppressive therapies, which inhibit re-epithelialization, fibroblast response, and collagen synthesis. Complete re-epithelialization was achieved with Grafix in 87% of the patients with a mean time to closure of 7 weeks.
